Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

Also called NCT03587558

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03587558
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03587558. Randomized; no masking; primary purpose treatment. Start 2017-09-05 (actual); primary completion 2019-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
Acronym
FOREVER
Condition
Ventricular Premature Complexes
Condition
Outflow Tract
Condition
Carvedilol
Intervention (Drug)
Carvedilol
Intervention (Drug)
Flecainide
Lead sponsor
Keimyung University Dongsan Medical Center (class: other)
Collaborator
Chong Kun Dang Pharmaceutical Corp. (class: industry)

Record details

Record id
cardio:ct-nct03587558
Content hash
0687e7595e2a890ab05cdc7a8d1684b0dc0521bb1859ad09d5f1f6afad2d375a